Boehringer takes over CA facility of client Amgen

Contract manufacturer Boehringer Ingelheim has formally taken ownership of the Fremont, CA, biopharma development and manufacturing facility of long-time client Amgen. The 200,000 square feet of lab, manufacturing and process development space represents a fully integrated site, which complements the CMO's sites in Biberach, Germany, and Vienna, Austria. The site is the work home of 300 employees. Announcement

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.